149 related articles for article (PubMed ID: 37695463)
1. Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors.
Schüttke V; Kusiek C; Fuessel S; Thomas C; Buerk BT; Erdmann K
Clin Transl Oncol; 2024 May; 26(5):1117-1128. PubMed ID: 37695463
[TBL] [Abstract][Full Text] [Related]
2. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
3. Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma.
Tachibana H; Nemoto Y; Ishihara H; Fukuda H; Yoshida K; Iizuka J; Hashimoto Y; Kondo T; Tanabe K; Takagi T
Clin Genitourin Cancer; 2022 Feb; 20(1):e81-e88. PubMed ID: 34772629
[TBL] [Abstract][Full Text] [Related]
4. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2020 May; 38(5):526-532. PubMed ID: 31864934
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
Kankkunen E; Penttilä P; Peltola K; Bono P
Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
7. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yasuda Y; Saito K; Yuasa T; Uehara S; Kawamura N; Yokoyama M; Ishioka J; Matsuoka Y; Yamamoto S; Okuno T; Yonese J; Kihara K; Fujii Y
Int J Clin Oncol; 2017 Dec; 22(6):1081-1086. PubMed ID: 28733795
[TBL] [Abstract][Full Text] [Related]
8. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
9. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
10. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Teishima J; Kobatake K; Shinmei S; Inoue S; Hayashi T; Ohara S; Mita K; Hasegawa Y; Maruyama S; Kajiwara M; Shigeta M; Mochizuki H; Moriyama H; Fujiwara S; Matsubara A
Urol Oncol; 2017 Nov; 35(11):662.e1-662.e7. PubMed ID: 28778585
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma.
Wang B; Gu W; Wan F; Shi G; Ye D
Int Braz J Urol; 2019; 45(1):89-99. PubMed ID: 29570259
[TBL] [Abstract][Full Text] [Related]
12. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
14. Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions.
Hoeh B; Garcia CC; Banek S; Klümper N; Cox A; Ellinger J; Schmucker P; Hahn O; Mattigk A; Zengerling F; Becker P; Erdmann K; Buerk BT; Flegar L; Huber J; Kalogirou C; Zeuschner P
Clin Transl Immunology; 2023; 12(10):e1471. PubMed ID: 37899949
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
16. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
19. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
[TBL] [Abstract][Full Text] [Related]
20. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]